# SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

> **NCT00091130** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 139 (actual)

## Conditions studied

- Atypical Squamous Cells of Undetermined Significance
- Cervical Cancer
- High-grade Squamous Intraepithelial Lesion
- Low-grade Squamous Intraepithelial Lesion

## Interventions

- **BIOLOGICAL:** HspE7
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00091130
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091130, "SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00091130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*